Citadel Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Citadel Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-230	Closed	-$1.61K	–	15657
2024 Q4	$1.61K	Sell	230 -760	-77%	-$8.35K	﹤0.01%	14167
2024 Q3	$14.4K	Buy	990 +380	+62%	+$17.1K	﹤0.01%	13025
2024 Q2	$44.5K	Buy	+610	New	+$46.9K	﹤0.01%	11897
2024 Q1	–	Sell	-1,540	Closed	-$113K	–	15499
2023 Q4	$113K	Buy	1,540 +1,420	+1,183%	+$58.3K	﹤0.01%	10780
2023 Q3	$4.66K	Sell	120 -1,320	-92%	-$67.1K	﹤0.01%	13467
2023 Q2	$83.1K	Sell	1,440 -2,640	-65%	-$160K	﹤0.01%	11198
2023 Q1	$265K	Sell	4,080 -1,890	-32%	-$114K	﹤0.01%	9629
2022 Q4	$164K	Buy	5,970 +4,180	+234%	+$112K	﹤0.01%	10464
2022 Q3	$52K	Buy	1,790 +290	+19%	+$9.94K	﹤0.01%	11600
2022 Q2	$29K	Buy	+1,500	New	+$75.4K	﹤0.01%	12247
2021 Q4	–	Sell	-2,560	Closed	-$320K	–	14830
2021 Q3	$320K	Buy	+2,560	New	+$287K	﹤0.01%	10924

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Citadel Advisors's VRCA Position: Q3 2025 in Review

Citadel Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 6,866 shares — an estimated $36.4K sold.

Citadel Advisors first reported a position in VRCA in Q1 2022 and held it in 10 quarters. The position peaked at $510K in Q2 2023. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

Citadel Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 6,866 Verrica Pharmaceuticals shares in Q3 2025, an estimated $36.4K.
Citadel Advisors first reported a position in Verrica Pharmaceuticals in Q1 2022 and held it in 10 quarters.
Citadel Advisors's Verrica Pharmaceuticals position peaked at $510K in Q2 2023.
34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.